Halogenated heteroaryl and other heterocyclic kinase inhibitors and uses thereof

The present invention relates to kinase inhibitors, in particular inhibitors of protein kinases, including CSF1R of the SIK family, ABL/BCR-ABL, SRC, HCK, PDGFR, KIT and/or mutants thereof. Although the kinase inhibitors of the present invention are structurally similar to dasatinib, the kinase inhibitors of the present invention are distinctive, having a particular class of halogenated heteroaryl groups. Such kinase inhibitors may exhibit one or more certain properties that differ from dasatinib and other structurally similar kinase inhibitors. The kinase inhibitors of the invention or pharmaceutical compositions comprising them can be used for the treatment of diseases or conditions, such as proliferative diseases, such as leukemia or solid tumors. In particular, these and other structurally similar kinase inhibitors can be used for the treatment of proliferative diseases, such as mixed phenotype acute leukemia (MPAL), characterized (inter alia) by the presence of MEF2C protein, human chromosomal translocat